(g) if so, what steps have been taken to check the same; and

(h) what are the names of injections which are being imported in the country which have monopoly-imports and which have annual import cost of more than Rupees one crore and what are the prices at which each is being sold ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Yes. Sir.

(b) Yes, Sir.

(c) M/s. Glaxo India Limited.

(d) Yes, Sir.

(e) Does not arise.

(f) Nothing has come to the notice of Government.

(g) Does not arise.

(h) Import of individual formulations are not being monitored by this Department.

Representations against wrong exclusion of Glybenclamide

2939. SMT. KAILASHPATI:
SMT. PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 915 given in the Rajya Sabha on 16th August, 1990 and state:

(a) what is the total number of representations received by his Ministry against wrong exclusion of Glybenclamide; and

(b) when the Standing Committee made recommendations on this drug and by when his Ministry would take a decision on these recommendations ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) About 22 representations from Hon'ble Members of Parliament have been received against exclusion of Glybenclamide from price control. The recommendation of the Standing Committee on this is under Governments' consideration.

Price control on small scale units

2940. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1425 given in the Rajya Sabha on 20th August, 1990 and state:

(a) whether it is a fact that the Kelkar Committee made certain observations about the functioning of Small Scale Units and their effect on consumer pricing:

(b) what is the reaction of his Ministry on those observations;

(c) whether it is a fact that Kelkar Committee recommended for price decontrol of Small Scale Units with turn over limitations;

(d) whether it is also a fact that Committee gave logical reasoning in support of their recommendations;

(e) what were the reasons for which his Ministry did not accept the Committee's recommendations:

(f) whether it is a fact that the value of production of bulk drugs is based on selling prices and value of imports on CIF prices; and

(g) what is the ex-factory value of production of bulk drugs for the last three years, yearwise ?